The role of hypoxia-activated prodrugs in cancer therapy

Lancet Oncology

Volumn 1, Issue 1, 2000, Pages 25-29

  Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NITROIMIDAZOLE DERIVATIVE; OXIDE; PRODRUG; QUINONE DERIVATIVE;

ANIMAL; CELL HYPOXIA; CHEMISTRY; HUMAN; NEOPLASM; PATHOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; HUMANS; NEOPLASMS; NITROIMIDAZOLES; OXIDES; PRODRUGS; QUINONES;

EID: 0034285733     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00006-1     Document Type: Review

References (28)

1. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer chemotherapy. Cancer Res. 58:1998;1405-1416.
2. Baish JW, Netti PA, Jain RK. Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc Res. 53:1997;128-141.
3. Overgaard J, Horsmann JR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitisers. Sem in Radiat Oncol. 6:1969;10-21.
4. Brown JM, Koong A. Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J Natl Cancer Inst. 83:1991;178-185.
5. Lash CJ, Li AE, Rutland M, et al. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer. 78:1998;439-445.
6. Denny WA, Wilson WR. Bioreducible mustards - a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev. 12:1993;135-151.
7. Denny WA, Wilson WR, Hay MP. Recent developments in the design of bioreductive drugs. Br J Cancer. 74:(suppl 27):1996;32-38.
8. Breider MA, Pilcher GD, Graziano MJ, et al. Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer. Toxicol Pathol. 26:1998;234-239.
9. Hay MP, Sykes BM, Denny WA, et al. A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro- 3H-benz[e]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. Bioorg Med Chem Lett. 15:1999;2237-2242.
10. Lee J, Siemann DW, Koch CJ, et al. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. Int J Cancer. 67:1996;372-388.
11. Knox RJ, Friedlos F, Boland MP. The bioactivation of CB-1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev. 12:1993;195-212.
12. Belcourt MF, Hodnick WF, Rockwell S, et al. Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH:cytochrome C (P-450) reductase and DT-diaphorase. Adv Enzyme Reg. 38:1998;111-133.
13. Tomasz M, Palom Y. The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther. 76:1997;73-87.
14. Haffty BG, Son YH, Wilson LD, et al. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. Radiat Oncol Invest. 5:1997;235-245.
15. Bailey SM, Wyatt MD, Friedlos F, et al. Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9. Br J Cancer. 76:1997;1596-1603.
16. Aamdal S, Lund B, Koier I, et al. Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG). Cancer Chemother Pharmacol. 45:2000;85-88.
17. Brown JM. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F Cain Memorial Award lecture. Cancer Res. 59:1999;5863-5870.
18. Hwang JT, Greenberg MM, Fuchs T, et al. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1′-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions. Biochemistry. 38:1999;14248-14255.
19. Hicks KO, Fleming Y, Siim BG, et al. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int J Radiat Oncol Biol Phys. 42:1998;641-649.
20. Lee DJ, Trotti A, Spencer S, et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. Int J Radiat Oncol Biol Phys. 42:1998;811-815.
21. Kovacs MS, Hocking DJ, Evans JW, et al. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer. 80:1999;1245-1251.
22. Gatzemeier U, Rodriguez G, Treat J, et al. Tirapazamine-cisplatin: the synergy. Br J Cancer. 77:(suppl 4):1998;15-17.
23. Treat J, Johnson E, Langer C, et al. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 16:1998;3524-3527.
24. Raleigh SM, Wanogho E, Burke MD, et al. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int J Radiat Oncol Biol Phys. 42:1988;763-767.
25. Patterson LH, Craven MR, Fisher GR, et al. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Oncol Res. 6:1994;533-538.
26. McKeown SR, Hejmadi MV, McIntyre IA, et al. AQ4N; an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer. 72:1995;76-81.
27. Ware DC, Palmer BD, Wilson WR, et al. Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins - synthesis and evaluation of cobalt(III) complexes of bidentate mustards. J Med Chem. 36:1993;1839-1846.
28. Anderson RF, Denny WA, Ware DC, et al. Pulse radiolysis studies on the mechanism of hypoxia-selective cytotoxicity of the cobalt(III)-nitrogen mustard complex SN 24771. Br J Cancer. 74:(suppl 27):1996;48-51.